During the last session, Akoya Biosciences Inc (NASDAQ:AKYA)’s traded shares were 0.33 million, with the beta value of the company hitting 1.38. At the end of the trading day, the stock’s price was $1.09, reflecting an intraday loss of -1.36% or -$0.01. The 52-week high for the AKYA share is $4.65, that puts it down -326.61 from that peak though still a striking 7.34% gain since the share price plummeted to a 52-week low of $1.01. The company’s market capitalization is $54.07M, and the average intraday trading volume over the past 10 days was 0.16 million shares, and the average trade volume was 311.37K shares over the past three months.
Akoya Biosciences Inc (AKYA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. AKYA has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.21.
Akoya Biosciences Inc (NASDAQ:AKYA) trade information
Akoya Biosciences Inc (AKYA) registered a -1.36% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.36% in intraday trading to $1.09, hitting a weekly high. The stock’s 5-day price performance is -3.98%, and it has moved by -35.42% in 30 days. Based on these gigs, the overall price performance for the year is -72.74%. The short interest in Akoya Biosciences Inc (NASDAQ:AKYA) is 2.32 million shares and it means that shorts have 8.53 day(s) to cover.
The consensus price target of analysts on Wall Street is $2.4, which implies an increase of 54.58% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.4 and $2.4 respectively. As a result, AKYA is trading at a discount of -120.18% off the target high and -120.18% off the low.
Akoya Biosciences Inc (AKYA) estimates and forecasts
In the rating firms’ projections, revenue will increase 11.06% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 19.95M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 22.28M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 18.35M and 23.16M respectively. In this case, analysts expect current quarter sales to grow by 8.70% and then drop by -3.82% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.03%. While earnings are projected to return 40.36% in 2025, the next five years will return 24.26% per annum.
AKYA Dividends
Akoya Biosciences Inc is due to release its next quarterly earnings on 2025-Mar-16. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Akoya Biosciences Inc (NASDAQ:AKYA)’s Major holders
Akoya Biosciences Inc insiders own 66.78% of total outstanding shares while institutional holders control 69.88%, with the float percentage being 210.34%. BLUE WATER LIFE SCIENCE ADVISORS, LP is the largest shareholder of the company, while 94.0 institutions own stock in it. As of 2024-06-30, the company held over 4.7 million shares (or 9.5058% of all shares), a total value of $10.99 million in shares.
The next largest institutional holding, with 1.5 million shares, is of BLACKROCK INC.’s that is approximately 3.039% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.51 million.
Also, the Mutual Funds coming in first place with the largest holdings of Akoya Biosciences Inc (AKYA) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 882.32 shares. This amounts to just over 1.77 percent of the company’s overall shares, with a $0.96 million market value. The same data shows that the other fund manager holds slightly less at 661.97, or about 1.33% of the stock, which is worth about $0.72 million.
